Sutro Biopharma combines strong sentiment and a favorable risk/reward asymmetry with a below-floor quality score, declining revenue, and options pricing that reflects a binary, high-volatility biotech name.
Thesis pillars
- Quality Floor Breach Cash Burn↓Deteriorating
- Analyst Upside Strong Momentum↑Improving
- Favorable Risk Reward Asymmetry→Stable
- +1 more pillar — see the Why tab for full reasoning
Sutro Biopharma, Inc. (STRO) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $22.43, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: STRO-004; Market cap $391M below $400M minimum.
Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) using its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+, which enable site-specific drug conjugation. The company's highest-priority wholly-owned... Read more
Hold if already holding. Not a fresh buy at $22.43, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: STRO-004; Market cap $391M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $391M below $400M minimum. Not in investable universe. Score 4.8/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Sutro Biopharma, Inc.
About Sutro Biopharma, Inc.
Sutro Biopharma's highest-priority wholly-owned product candidate, STRO-004, an antibody-drug conjugate targeting tissue factor, entered a Phase 1 trial in November 2025 after receiving FDA IND clearance the prior month, with initial data expected in mid-2026. The company has generated no product revenue and instead has received approximately $1.016 billion in aggregate payments across its research collaborations with Astellas, Merck, Bristol Myers Squibb, and EMD Serono. Preclinical programs STRO-006 and STRO-227 could support IND filings in 2026 and late 2026 or early 2027, respectively.
Sutro's revenue has historically come from multitarget research collaborations built on its XpressCF and XpressCF+ platforms rather than product sales: partnerships with Merck, Bristol Myers Squibb (via Celgene), and EMD Serono each advanced a development candidate into clinical trials, but all three partners elected to terminate further development after Phase 1 studies as part of their own portfolio reviews. Astellas remains an active collaborator on immunostimulatory ADCs, with the first program entering clinical development in the first quarter of 2026. Sutro also deprioritized its own former lead asset, luveltamab tazevibulin, in March 2025 after a strategic portfolio review, and terminated its 2024 Ipsen license covering STRO-003 in 2025, leaving STRO-004 as the company's clinical-stage focus.
Show full overview
Sutro's near-term value is concentrated in a single wholly-owned, single-indication asset: STRO-004 is the company's highest-priority program, targeting tissue factor in solid tumors, and every other wholly-owned candidate — STRO-006 and STRO-227 — remains preclinical. Because three prior partnered candidates derived from the same XpressCF platform each cleared Phase 1 only to be shelved by BMS, Merck, and EMD Serono during strategic reviews, a similarly disappointing readout from the STRO-004 Phase 1 trial, expected in mid-2026, would leave Sutro without a clinical-stage wholly-owned program to fall back on.
See also: Healthcare · Biotechnology
From Sutro Biopharma, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineSTRO-00410-K Item 1: 'Our highest priority wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Revenue shrinking — -16.5% YoY. Growth thesis broken unless recovery story develops.static
Unprofitable operations — net margin -154.2%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $22.43, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: STRO-004; Market cap $391M below $400M minimum. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $391M below $400M minimum. Not in investable universe. Target $41.54 (+85.2%), stop $21.07 (−6.5%), A.R:R 5.7:1. Score 4.8/10, moderate confidence.
Take-profit target: $41.54 (+84.7% upside). Target $41.54 (+85.2%), stop $21.07 (−6.5%), A.R:R 5.7:1. Stop-loss: $21.07.
Concentration risk — Pipeline: STRO-004; Market cap $391M below $400M minimum.
Sutro Biopharma, Inc. trades at a P/E of N/A (forward -3.4). TrendMatrix value score: 8.4/10. Verdict: Hold.
19 analysts cover STRO with a consensus score of 4.1/5. Average price target: $48.
What does Sutro Biopharma, Inc. do?Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) using its proprietary...
Sutro Biopharma is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) using its proprietary cell-free protein synthesis platforms, XpressCF and XpressCF+, which enable site-specific drug conjugation. The company's highest-priority wholly-owned candidate, STRO-004, entered Phase 1 trials in November 2025 after prior partnered programs with Merck, Bristol Myers Squibb, and EMD Serono were discontinued following Phase 1 by those partners; Sutro has received approximately $1.016 billion in aggregate collaboration payments to date.